Hyperfine, Inc. (HYPR)
NASDAQ: HYPR · Real-Time Price · USD
0.970
-0.010 (-1.02%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States.
The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services.
It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.
Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
Hyperfine, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Maria Sainz |
Contact Details
Address: 351 New Whitfield Street Guilford, Connecticut 06437 United States | |
| Phone | 866 796 6767 |
| Website | hyperfine.io |
Stock Details
| Ticker Symbol | HYPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833769 |
| CUSIP Number | 44916K106 |
| ISIN Number | US44916K1060 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Maria Sainz | Chief Executive Officer, President and Director |
| R. Scott Huennekens CPA, M.B.A. | Executive Chairman |
| Dr. Jonathan M. Rothberg Ph.D. | Founder and Vice Chairman |
| Brett Hale | Chief Administrative Officer, Chief Financial Officer, Chief Compliance Officer, Treasurer and Corporate Secretary |
| Dr. Thomas Teisseyre Ph.D. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 24, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |